{
    "links": "https://www.ycombinator.com/companies/ochre-bio",
    "name": "Ochre Bio",
    "headline": "RNA medicines for liver diseases",
    "batch": "W20",
    "description": "Ochre Bio is a biotechnology company developing RNA medicines for chronic liver diseases.",
    "activity_status": "Active",
    "website": "https://www.ochre-bio.com/",
    "founded_date": 2019.0,
    "team_size": 50.0,
    "location": "Oxford, United Kingdom",
    "group_partner": null,
    "group_partner_yc": null,
    "company_linkedin": null,
    "company_twitter": null,
    "tags": "industry:biotech; industry:genomics",
    "founders": [],
    "status": true,
    "generated_description": "**Ochre Bio** is a promising biotechnology company founded in 2019, situated in Oxford, United Kingdom. Known for its forward-thinking approach, the company specializes in developing RNA medicines targeting chronic liver diseases. This venture is particularly timely, given that chronic liver disease is increasingly recognized as a leading cause of premature death globally.\n\nPart of the Y Combinator Batch W20, Ochre Bio operates with a dedicated team of about 50 skilled professionals. Their mission is clear: to use human models to generate significant genomic and phenotypic data, creating innovative RNA therapies to address critical challenges in liver health. The statistics are alarming\u2014chronic liver disease not only affects millions but is also the only condition among the top ten global killers that is on the rise.\n\nWhat sets Ochre Bio apart is its advanced scientific methodology. They employ a powerful combination of computational and multi-omic technologies to dive deep into the complexities of liver biology, proving themselves capable of quickly turning human data into potential therapies\u2014moving from target to validated lead in weeks, not years.\n\nThe company is backed by a strong scientific team with decades of experience in genomics and drug discovery, reinforcing their commitment to tackling unmet medical needs for patients with late-stage liver disease. As they continue to push the boundaries of what's possible in RNA therapeutics, Ochre Bio is positioned as a key player in the future of liver disease treatment.\n\nFor more information, you can visit their [website](https://www.ochre-bio.com/).",
    "logo": "https://bookface-images.s3.us-west-2.amazonaws.com/logos/91514d639cb34a30c9f95f9bcf291d1c461aaca3.png?X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Credential=ASIAQC4NIECAJMV6TLGB%2F20250221%2Fus-west-2%2Fs3%2Faws4_request&X-Amz-Date=20250221T191605Z&X-Amz-Expires=3600&X-Amz-Security-Token=IQoJb3JpZ2luX2VjELP%2F%2F%2F%2F%2F%2F%2F%2F%2F%2FwEaCXVzLXdlc3QtMiJGMEQCIFLa1ybFb1MW3YWarl6N2DZLtQ4R6h64JtRzg2nxAowaAiB3nTk9Wj2wgaQBuQdmXKSYUK01s%2FfzNcIsI%2FpnnVYrDCruAwjc%2F%2F%2F%2F%2F%2F%2F%2F%2F%2F8BEAAaDDAwNjIwMTgxMTA3MiIMbK4eHGyZbeOmKiEOKsIDEgeFqYzoIm9WYPES%2BanLfTcQEGyzIks%2Fal2Lmqxe4p56ewXYsETQE6xKLCXrmvzZNyUDpx5dtkyRoWAO6FYyXXGaPQzEZ3lyFdj%2BxmzYPjn73zyfO0POWT06n60Ss4FWi%2BsXTCqzCDlztmj5P3pe%2BccFf3AJ6Fob0iUEcgWZg86XqS2niw4lXPnalb%2Boq3NuXvHl2oVLzjcW3kqbNIZD4bJeuP%2BaiX3YtJ%2BJXjqRV4JMYzbegC89ld8%2FQ6Niu9GP6iWyA3Ij%2Frc6v9eF94GLnVFmDUIq%2FgOldm3US8WLOYW64cbfEYgRv4%2BZqFOZik7gMqvr0%2BAMO66zctStkeS7pQEndome2HMXzolZnAHIKHa7syJwRucmMBn1qLVqGHDFwDTWD66ZqASdClXaJEb6qKYFGBQM0HPz9IZYPkFD7FlZyifcWNrFEjlM4LJiyAQcunx30b5EMcz8oT7YjYIo5Bb2DOsnIt6uAdkOmUPUmY%2FzM3PmuL6ZYePw7XBzfBYcfiNqZPHWFO6x0%2FmP5sl5TFTspcBFiC1tU5q9L40pvlUpeAHA0lByHoziRM9b9aIUnBzO8cEmGGLYvEv9AlDEIduUMLKL470GOqYBeuzvU%2B1K1xvzamOk1TaDeko%2BJlQ8xUgcguCKvnE%2BpYSn9MQz0SIXrm4hUrSnIO%2FjFoTZ4esBSlXTCkXH%2F6%2BRHttOAoEAfv1XQWO8%2Bsv2qVS97SrODEBLVhY1tfEFQcw%2BZ93GUo5LYHe1U2PubGkf9wTLJ5AZCq5Vr1%2FKLwVlulVfHEhtz4E3fzOL1TPO7tIclZor0kZmzjAwtkky7VHrQVXehNV3Gw%3D%3D&X-Amz-SignedHeaders=host&X-Amz-Signature=8a6f226ae2d492dad20898410cb642c54734a2ea7400b329bc38e1d021775d79",
    "social_links": [
        "https://www.linkedin.com/company/ochre-bio",
        "https://twitter.com/OchreBio"
    ],
    "logo_path": "data/logos\\Ochre_Bio_logo.png"
}